Learning Objectives:

1. Review the use of neoadjuvant chemotherapy for HER2 negative breast cancer

2. Identify known predictors of response to neoadjuvant therapy

3. Discuss the promise of deep learning on digital pathology as a tool to identify responders to neoadjuvant treatment

Session date: 
Monday, September 21, 2020 - 12:00pm to 1:00pm
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Frederick M. Howard, M.D.